FinData: News for NASDAQ, AVII - AVI BioPharma Inc.

Sunday, 26 May 2013

AVI BioPharma Inc.

Recent News

Sarepta Therapeutics Inc Names Sandy Mahatme Senior Vice President, Chief Financial Officer
10:05 | 6/11/12

Reuters Key Development
Sarepta Therapeutics Inc Names Sandy Mahatme Senior Vice President, Chief Financial Officer more»
Stocks to Watch (SRPT, DCM, BMRN, SQNM, QTM)
01:54 | 2/11/12

Mesh Press
NEW YORK, November 01,2012 (MESHPRESS) - Csrnewsdaily.com, an investor research portal specializing in several sectors including biotech and healthcare and tech stocks on the U.S. more»
Sarepta Therapeutics Announces Third Quarter 2012 Financial Results and ...
09:29 | 31/10/12

MarketWatch
CAMBRIDGE, MA, Oct 30, 2012 (MARKETWIRE via COMTEX) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT) , a developer of innovative RNA-based therapeutics, will report third quarter 2012 financial results after the NASDAQ Global Market closes on ... more»
Sarepta Therapeutics: Are We There Yet?
05:53 | 27/10/12

Forex Pros
In the beginning of October Sarepta Therapeutics (SRPT) created a buzz among bio-stock traders and investors jumping up 200% in one day after releasing positive results for its Duchenne muscular dystrophy drug candidate eteplirsen from the phase IIb ... more»
Sarepta Part I: The Possibility Of An Accelerated Approval Of Eteplirsen
15:11 | 24/10/12

Seeking Alpha
Carolyn Da Wang and Andrew McDonald, Ph.D. Sarepta Therapeutics (NASDAQ: SRPT) develops RNA-based therapeutics for rare genetic disorders and is a rising star in the orphan drug space, which is dominated by companies like Alexion (ALXN), ... more»
Frustrating Trading Session For Sarepta
05:33 | 24/10/12

SmallCap Network
It's been a frustrating trading session for anyone who was faithful to Sarepta Therapeutics (NASDAQ: SRPT) after the company released solid phase II trial data for their flagship drug etiplirsen on October 3rd, which sparked an immense rally that ... more»
Price Alert: SRPT nearing the 20MA (NASDAQ:SRPT)
06:30 | 17/10/12

Inthemoneystocks.com (blog)
Sarepta Therapeutics Inc (NASDAQ:SRPT) is inching towards the daily 20 moving average. This represents the first decent support level since the stock went parabolic two weeks ago. more»
Price Alert: SRPT nearing the 20MA
06:29 | 17/10/12

Inthemoneystocks.com (blog)
Sarepta Therapeutics Inc (NASDAQ:SRPT) is inching towards the daily 20 moving average. This represents the first decent support level since the stock went parabolic two weeks ago. more»
Healthcare Business Update: Sarepta Presents Data, Pharmacyclics Enrolls 5th ...
12:13 | 16/10/12

Wall St. Cheat Sheet
Sarepta Therapeutics (SRPT) presented phase IIb data over the weekend indicating that its eteplirsen treatment for Duchenne Muscular Dystrophy is effective. more»
Wedbush Gives Outperform Rating to Sarepta Therapeutic (SRPT)
07:54 | 16/10/12

Jags Report
Sarepta Therapeutic logo Wedbush reissued their outperform rating on shares of Sarepta Therapeutic (NASDAQ: SRPT) in a research report released on Monday morning. more»

Global Indices

Code	Last	Change
NZ50	4,526	62	1.36%
COMP	3,459	0	0.01%
DJI	15,303	9	0.06%
SP500	1,650	1	0.06%
DAX	7,789	91	1.15%
FTSE	6,654	42	0.63%
NI225	12,494	22	0.18%
TWI	76.22	0.16	0.21%

More news...

No news available...

Currencies

Code	Last	Change
EURUSD	1.294	0.001	0.04%
NZDUSD	0.8093	0.0013	0.16%
AUDUSD	0.9651	0.0093	0.95%
NZDAUD	0.8385	0.0028	0.34%